Health
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants – PharmiWeb.com
The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase…
- The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine
- Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant sequence; this would provide a flexible solution for rapidly adapting the vaccine for use against the B.1.351 lineage or…
Continue Reading
-
Noosa News18 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
Noosa News23 hours agoScientists move precious ReefHQ coral ahead of Great Barrier Reef Aquarium build
-
General23 hours agoNew Spirit of Tasmania ferry arrives in Hobart, but will not be operating for more than a year
-
General24 hours agoWA government is ‘spinning’ the results of community survey into Burswood Park racetrack and community hub, locals say